使用伽马分泌酶调节剂的显性遗传 AD 网络体外试验-猫眼课题宝

使用伽马分泌酶调节剂的显性遗传 AD 网络体外试验

批准号：

9795379

负责人：

Steven Lee Wagner

金额：

$0.0万

依托单位：

VA SAN DIEGO HEALTHCARE SYSTEM

依托单位国家：

美国

项目类别：

财政年份：

2017

资助国家：

美国

项目状态：

已结题

起止时间：

2017-06-01 至 2021-05-31

来源：

https://reporter.nih.gov/project-details/9795379

关键词：

Affect Alzheimer&apos s Disease Alzheimer&apos s Disease Pathway Amyloid beta-Protein Animal Model Award Axon Axonal Transport Biological Markers Brain-Derived Neurotrophic Factor Cell model Cells Clinical Trials Collaborations DNA Sequence Alteration Development Diagnosis Digit structure Disease Disease Progression Dose Early Endosome Early Onset Familial Alzheimer&apos s Disease Effectiveness Enrollment Evaluation Event Failure Fibroblasts Functional disorder Funding Generations Goals Human In Vitro Inherited Investigational Drugs Late Onset Alzheimer Disease Lead Link MAPT gene Measures Mediating Methods Modeling Mus Mutation Neurofibrillary Tangles Neurons No-Observed-Adverse-Effect Level Non-Steroidal Anti-Inflammatory Agents Onset of illness Pathology Patients Pharmaceutical Preparations Phase Phase I Clinical Trials Phase II Clinical Trials Prevention trial Primary Prevention Process Production Rattus Rodent Rodent Model Secure System Testing Therapeutic Therapeutic Index Toxic effect Toxicity Tests Toxicology United States National Institutes of Health Veterans abeta accumulation axonopathy base clinical candidate cohort drug development efficacy study efficacy testing extracellular gamma secretase good laboratory practice hyperphosphorylated tau improved in vivo induced pluripotent stem cell inhibitor/antagonist mutant mutation carrier neuropathology non-demented nonhuman primate novel patient population preclinical evaluation presenilin-1 resistance mutation response safety testing side effect small molecule success tau Proteins

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

Alzheimer’s disease (AD) is defined neuropathologically by extracellular plaques composed of β-amyloid (Aβ42) and intracellular tangles consisting of hyperphosphorylated forms of the microtubule-associated protein tau. Aβ accumulation and hyperphosphorylation of tau are recognized as key events leading to full blown AD neuropathology. Here we propose comprehensive in vitro analysis of a unique set of novel small molecule drugs known gamma- secretase modulators (GSMs) to further explore AD therapeutics. This proposal will focus on testing an optimal lead clinical candidate for efficacy in human neurons aimed at halting Aβ42- related pathologies AD. Our overarching hypothesis is GSM therapy aimed to disrupt production of Aβ42 will be an efficacious treatment approach for prodromal or early AD, as well as sporadic late-onset AD. The goal of this project is to validate target engagement in human neurons from selected patients.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文